EAM
STRO icon

Exome Asset Management’s Sutro Biopharma STRO Stock Holding History

Exome Asset Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-15,360
Closed -$659K – 71
2023
Q4 		$659K Buy
+15,360
New +$487K 0.65% 44

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Exome Asset Management's STRO Position: Q1 2024 in Review

Exome Asset Management sold out of Sutro Biopharma (STRO) in Q1 2024, closing a stake of 15,360 shares — an estimated $659K sold.

Exome Asset Management first reported a position in STRO in Q4 2023 and held it in 1 quarter. The position peaked at $659K in Q4 2023. 117 funds tracked by Wall St. Rank hold STRO as of Q1 2024.

  • Exome Asset Management reported no remaining Sutro Biopharma position as of Q1 2024 after selling out during the quarter.
  • Exome Asset Management sold 15,360 Sutro Biopharma shares in Q1 2024, an estimated $659K.
  • Exome Asset Management first reported a position in Sutro Biopharma in Q4 2023 and held it in 1 quarter.
  • Exome Asset Management's Sutro Biopharma position peaked at $659K in Q4 2023.
  • 117 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2024.

Based on Exome Asset Management's 13F filing for Q1 2024, filed 15 May 2024.